55 -3 (77) 2025 - A.A.Mamarizaev, U.M.Rustamov - THE ROLE OF THE G2014A/THR594THR POLYMORPHISM IN THE ESR1 GENE IN THE PATHOGENESIS OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER

THE ROLE OF THE G2014A/THR594THR POLYMORPHISM IN THE ESR1 GENE IN THE PATHOGENESIS OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER

A.A.Mamarizaev - Andijan State Medical Institute

U.M.Rustamov - Andijan State Medical Institute

Resume

This thesis investigates the role of the G2014A/Thr594Thr polymorphism in the ESR1 gene in the development of Benign Prostatic Hyperplasia (BPH) and Prostate Cancer (PC). The ESR1 gene encodes the estrogen receptor alpha (ERα), which plays a critical role in the regulation of cellular processes influenced by estrogen signaling. The G2014A polymorphism results in the Thr594Thr substitution, a variation that may affect receptor function and, consequently, influence prostate tissue growth and disease progression. The research explores whether this genetic variation contributes to the pathogenesis of BPH, a non-cancerous enlargement of the prostate, and PCa, a hormone-dependent malignancy. The study will also examine potential molecular mechanisms through which the polymorphism alters estrogen receptor activity and its effects on prostate cell proliferation, apoptosis, and androgen receptor signaling. By clarifying the role of this polymorphism, the thesis aims to provide insights into the genetic underpinnings of prostate diseases, with potential implications for risk assessment, early detection, and targeted therapies.

Keywords: Benign Prostatic Hyperplasia (BPH), prostate cancer, genetic polymorphisms, ESR1 gene, G2014A/Thr594Thr Polymorphism.

First page

297

Last page

302

For citation:A.A.Mamarizaev, U.M.Rustamov - THE ROLE OF THE G2014A/THR594THR POLYMORPHISM IN THE ESR1 GENE IN THE PATHOGENESIS OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER//New Day in Medicine 3(77)2025 297-302 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

1. Alcaraz A., Carballido-Rodrigues J. Quality of Life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment- the Qualiprost study // Int Urol Nephrol. 2016. May:48(5):645-56. https://www.ncbi.nlm.nih.gov/pubmed/26810324
2. Joniau S., Briganti A., Gontero P. et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study // Eur Urol. 2015; 67(1):157-164.
3. Kim E.H. J.A. Brockman, Andriole G.L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia // Asian J. Urol. 2018;5(1):28-32.
4. Lim K.B. Epidemiology of clinical benign prostatic hyperplasia // Asian J Urol. 2017. Jul.4(3):148-151. https://www.ncbi.nlm.nih.gov/pubmed/29264223
5. Rawla P. Epidemiology of Prostate Cancer/ P.Rawla // World J Oncol. 2019;10(2):63-89.
6. Shih H.J., Huang C.J., Lin J.A. et al. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia // Prostate. 2018;78(2):113-120.
7. Sissung T.M., Price D.K., Del Re M. et al. (2014): Genetic variation: effect on prostate cancer // Biochim. Biophys. Acta 1846, 2014; 446-456.
8. Sivonova M. K., Jurečekova J., Tatarkova Z. et al. The role of CYP17A1 in prostate cancer development: structure, function, mechanism of action, genetic variations and its inhibition // Gen. Physiol. Biophys. 2017;36:487-499. doi: 10.4149/gpb_2017024
9. Vuichoud C., Loughlin K.R. Benign Prostatic Hyperplasia: epidemiology, economics and evaluation // Can J Urol. 2015;22(Suppl 1):1-6.
10. Wang G. et al. Genetics and biology of prostate cancer // Genes Dev. 2018;32(17-18):1105-1140.

    file

    download